Complement activation in vascular remodeling and organ damage

Drug Discovery Today: Disease Mechanisms

Volumn 5, Issue 3-4, 2008, Pages

  Shagdarsuren, Erdenechimeg ^a   Müller, Dominik ^b   Weber, Christian ^a   Zernecke, Alma ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; LOW DENSITY LIPOPROTEIN;

ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; COMPLEMENT DEFICIENCY; COMPLEMENT SYSTEM; ENDOTHELIUM CELL; HUMAN; LIPID STORAGE; MACROPHAGE ACTIVATION; NONHUMAN; ORGAN INJURY; PROTEIN FUNCTION; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; THROMBOCYTE ACTIVATION; VASCULAR SMOOTH MUSCLE;

EID: 67649394359     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2008.09.006     Document Type: Review

References (56)

1. Ward M.R., et al. Arterial remodeling. Mechanisms and clinical implications. Circulation 102 (2000) 1186-1191
2. Schoenhagen P., et al. Arterial remodeling and coronary artery disease: the concept of "dilated" versus "obstructive" coronary atherosclerosis. J. Am. Coll. Cardiol. 38 (2001) 297-306
3. Shagdarsuren E., et al. C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosis-prone mice. Circulation 117 (2008) 70-78
4. Wehner J., et al. Antibody and complement in transplant vasculopathy. Circ. Res. 100 (2007) 191-203
5. Shagdarsuren E., et al. Complement activation in angiotensin II-induced organ damage. Circ. Res. 97 (2005) 716-724
6. Oksjoki R., et al. Function and regulation of the complement system in cardiovascular diseases. Front Biosci. 12 (2007) 4696-4708
7. Niculescu F., and Rus H. The role of complement activation in atherosclerosis. Immunol. Res. 30 (2004) 73-80
8. Yasojima K., et al. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1214-1219
9. Schmiedt W., et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1790-1795
10. Patel S., et al. ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. Biochem. Biophys. Res. Commun. 286 (2001) 164-170
11. Buono C., et al. Influence of C3 deficiency on atherosclerosis. Circulation 105 (2002) 3025-3031
12. Persson L., et al. Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1062-1067
13. Meuwissen M., et al. Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J. Clin. Pathol. 59 (2006) 196-201
14. Torzewski M., et al. Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2130-2136
15. Onat A., et al. Cross-sectional study of complement C3 as a coronary risk factor among men and women. Clin. Sci. (Lond.) 108 (2005) 129-135
16. van Oostrom A.J., et al. Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. Drugs 64 Suppl. 2 (2004) 19-41
17. Kostner K.M., et al. Inflammation, complement activation and endothelial function in stable and unstable coronary artery disease. Clin. Chim. Acta 365 (2006) 129-134
18. Speidl W.S., et al. Complement component C5a predicts restenosis after superficial femoral artery balloon angioplasty. J. Endovasc. Ther. 14 (2007) 62-69
19. Cianflone K., et al. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim. Biophys. Acta 1609 (2003) 127-143
20. Meijssen S., et al. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 811-816
21. Verseyden C., et al. Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia. J. Lipid Res. 44 (2003) 2100-2108
22. Halkes C.J., et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1526-1530
23. Schepers A., et al. Inhibition of complement component C3 reduces vein graft atherosclerosis in apolipoprotein E3-Leiden transgenic mice. Circulation 114 (2006) 2831-2838
24. Tulamo R., et al. Complement activation associates with saccular cerebral artery aneurysm wall degeneration and rupture. Neurosurgery 59 (2006) 1069-1076 (discussion 1076-1077)
25. Capella J.F., et al. Complement activation and subclassification of tissue immunoglobulin G in the abdominal aortic aneurysm. J. Surg. Res. 65 (1996) 31-33
26. Pasterkamp G., et al. Expansive arterial remodeling: location, location, location. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 650-657
27. Fischetti F., and Tedesco F. Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases. Autoimmunity 39 (2006) 417-428
28. Peerschke E.I., et al. Expression of gC1q-R/p33 and its major ligands in human atherosclerotic lesions. Mol. Immunol. 41 (2004) 759-766
29. Soares M.P., and Bach F.H. C1q receptors and endothelial cell activation. J. Lab. Clin. Med. 133 (1999) 520-522
30. Bhatia V.K., et al. Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am. J. Pathol. 170 (2007) 416-426
31. Monsinjon T., et al. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J. 17 (2003) 1003-1014
32. Laudes I.J., et al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J. Immunol. 169 (2002) 5962-5970
33. Schraufstatter I.U., et al. Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J. Immunol. 169 (2002) 2102-2110
34. Acosta J., et al. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr. Pharm. Des. 10 (2004) 203-211
35. Urbich C., et al. Laminar shear stress upregulates the complement-inhibitory protein clusterin: a novel potent defense mechanism against complement-induced endothelial cell activation. Circulation 101 (2000) 352-355
36. Addis-Lieser E., et al. Opposing regulatory roles of complement factor 5 in the development of bleomycin-induced pulmonary fibrosis. J. Immunol. 175 (2005) 1894-1902
37. Hillebrandt S., et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat. Genet. 37 (2005) 835-843
38. Owens G.K., et al. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84 (2004) 767-801
39. Zeiffer U., et al. Neointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokines. Circ. Res. 94 (2004) 776-784
40. Torzewski J., et al. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 673-677
41. Viedt C., et al. The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1. FASEB J. 14 (2000) 2370-2372
42. Ueda Y., et al. Production of the third and fourth component of complement (C3, C4) by smooth muscle cells. Immunology 89 (1996) 183-188
43. Viedt C., et al. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. Basic Res. Cardiol. 98 (2003) 353-361
44. Lin Z.H., et al. Complement 3 is involved in the synthetic phenotype and exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 44 (2004) 42-47
45. Zwaka T.P., et al. The terminal complement complex inhibits apoptosis in vascular smooth muscle cells by activating an autocrine IGF-1 loop. FASEB J. 17 (2003) 1346-1348
46. Torzewski M., et al. Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 2448-2452
47. Boyle J.J., et al. Human blood-derived macrophages induce apoptosis in human plaque-derived vascular smooth muscle cells by Fas-ligand/Fas interactions. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1402-1407
48. Bajtay Z., et al. Mannan-binding lectin and C1q bind to distinct structures and exert differential effects on macrophages. Eur. J. Immunol. 30 (2000) 1706-1713
49. Higuchi H., et al. Complement receptor type 3 (CR3)- and Fc receptor (FcR)-mediated matrix metalloproteinase 9 (MMP-9) secretion and their intracellular signalling of bovine neutrophils. Vet. Res. Commun. 31 (2007) 985-991
50. DiScipio R.G., et al. C5a mediates secretion and activation of matrix metalloproteinase 9 from human eosinophils and neutrophils. Int. Immunopharmacol. 6 (2006) 1109-1118
51. Strainic M.G., et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28 (2008) 425-435
52. Yin W., et al. Expression of complement components and inhibitors on platelet microparticles. Platelets 19 (2008) 225-233
53. Kastl S.P., et al. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation. J. Thromb. Haemost. 4 (2006) 1790-1797
54. Wojta J., et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 100 (2002) 517-523
55. Verdeguer F., et al. Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation. Cardiovasc. Res. 76 (2007) 340-350
56. Sampietro T., et al. Upregulation of the immune system in primary hypercholesterolaemia: effect of atorvastatin therapy. J. Intern. Med. 257 (2005) 523-530